PATENT CLAIM ANALYSIS

Application Number: 15772919
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "394000"]

Abstract:
The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof and its use in therapy.

Claim (Index 45):
A method of treating a subject suffering from cancer, autoimmune diseases, allergic diseases, inflammatory diseases, viral infection or combinations thereof, wherein the enzymatic activity of ITK, RLK or both are reduced by administering to the subject a therapeutically effective amount of the compound of  claim 1  or a pharmaceutically acceptable salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 93.0
- Lexical Diversity: 1.49123
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15262193', '14404497', '14412982', '15037923', '14009635']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8143762462854872
- 35 USC 102 Novelty (BERT): 0.5344655676382298
- Combined Prediction Score: 0.7863851784207614
- Mean Citation Score: 352.284728
- Max Citation Score: 364.62503
- Similarity Product: 203.9329991267592

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test